Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Introduction The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization...
Uloženo v:
| Vydáno v: | Critical care (London, England) Ročník 15; číslo 6; s. R267 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
15.11.2011
BioMed Central Ltd |
| Témata: | |
| ISSN: | 1364-8535, 1466-609X, 1364-8535, 1466-609X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Introduction
The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs.
Methods
A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)).
Results
Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (
n
= 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23).
Conclusions
No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. |
|---|---|
| AbstractList | The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs.
A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)).
Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23).
No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. Introduction The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs. Methods A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)). Results Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia ( n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23). Conclusions No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. Introduction The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs. Methods A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)). Results Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23). Conclusions No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs. A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)). Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23). No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs.INTRODUCTIONThe optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs.A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)).METHODSA search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)).Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23).RESULTSTwenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23).No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings.CONCLUSIONSNo significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings. |
| ArticleNumber | R267 |
| Audience | Academic |
| Author | Fowler, Robert A Daneman, Nick Havey, Thomas C |
| AuthorAffiliation | 2 Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, University of Toronto, M4N 3N5 Canada 3 Division of Infectious Diseases, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, University of Toronto, M4N 3N5 Canada 1 Department of Medicine, University of Toronto, 1 Kings College Circle, O, M5S 1A8, Canada |
| AuthorAffiliation_xml | – name: 2 Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, University of Toronto, M4N 3N5 Canada – name: 3 Division of Infectious Diseases, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, University of Toronto, M4N 3N5 Canada – name: 1 Department of Medicine, University of Toronto, 1 Kings College Circle, O, M5S 1A8, Canada |
| Author_xml | – sequence: 1 givenname: Thomas C surname: Havey fullname: Havey, Thomas C organization: Department of Medicine, University of Toronto, 1 Kings College Circle, O – sequence: 2 givenname: Robert A surname: Fowler fullname: Fowler, Robert A organization: Department of Medicine, University of Toronto, 1 Kings College Circle, O, Department of Critical Care Medicine,University of Toronto, Sunnybrook Health Sciences Centre – sequence: 3 givenname: Nick surname: Daneman fullname: Daneman, Nick email: nick.daneman@sunnybrook.ca organization: Department of Medicine, University of Toronto, 1 Kings College Circle, O, Division of Infectious Diseases,University of Toronto, Sunnybrook Health Sciences Centre |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22085732$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1rHSEUhqWkNB8t_QdloIt2M6mfM9pFIaSfEOgmXYvjHG8MM3qrTsr99_Xm3qQJKS4UfXzw-J5jdBBiAIReE3xKiOw-WEuw4OIZOiKs460UTBw8WB-i45yvMSa97NgLdEgplqJn9Ahdfl6SKT6GJrrGhOIHH4u3TbmCZNabxsXUDMYWSDB787ExTd7kArPZQgluPPyp18ZmhmJaE8y0yT6_RM-dmTK82s8n6NfXL5fn39uLn99-nJ9dtFYwXlo1SipHQ5nEQ-86KyzHbrAjcMaUxCOMtBN4gIErUJj3A5BeUScU5z0jGNgJ-rTzrpdhhtFCKMlMep38bNJGR-P145Pgr_Qq3mjGpOwEq4J3e0GKvxfIRc8-W5gmEyAuWSuhCFP0lny7I1dmAu2Di1Vot7Q-oz3nrJdCVOr0P1QdY_09WyNzvu4_uvDmYQX3T78LqALtDrAp5pzAaevLbWDV7CdNsN42gN43wL-K7vk75VPy_Y7MlQgrSPo6LqkmmJ-gfwHopbxW |
| CitedBy_id | crossref_primary_10_1111_vec_12272 crossref_primary_10_1111_jpc_13518 crossref_primary_10_1097_PCC_0000000000002198 crossref_primary_10_1177_0897190018792797 crossref_primary_10_1097_QCO_0000000000000140 crossref_primary_10_1016_j_lpm_2016_03_006 crossref_primary_10_1097_INF_0000000000001063 crossref_primary_10_1016_S1473_3099_24_00456_0 crossref_primary_10_1097_CCM_0000000000001393 crossref_primary_10_3390_microorganisms9071401 crossref_primary_10_1055_a_2078_3265 crossref_primary_10_1586_14787210_2015_1008451 crossref_primary_10_1016_j_ijantimicag_2019_05_014 crossref_primary_10_1093_cid_ciab116 crossref_primary_10_1155_2017_8634717 crossref_primary_10_1007_s11739_016_1560_1 crossref_primary_10_1093_jac_dky352 crossref_primary_10_1097_CCM_0000000000001898 crossref_primary_10_1186_s13054_014_0480_6 crossref_primary_10_3390_antibiotics12081262 crossref_primary_10_1089_sur_2016_261 crossref_primary_10_1016_j_jinf_2018_09_004 crossref_primary_10_1017_ash_2025_10054 crossref_primary_10_1186_s13054_016_1285_6 crossref_primary_10_1186_s12879_020_05132_1 crossref_primary_10_1016_j_cmi_2015_05_013 crossref_primary_10_1111_jcpt_13277 crossref_primary_10_12788_jhm_2905 crossref_primary_10_1007_s00101_017_0363_8 crossref_primary_10_1080_14787210_2019_1581607 crossref_primary_10_1007_s13546_014_0916_7 crossref_primary_10_1093_ofid_ofy087 crossref_primary_10_5495_wjcid_v10_i3_33 crossref_primary_10_1186_cc10590 crossref_primary_10_1177_1024907919890495 crossref_primary_10_1016_j_cmi_2021_10_022 crossref_primary_10_5694_mja14_01201 crossref_primary_10_1007_s00134_020_05950_6 crossref_primary_10_1371_journal_pone_0197302 crossref_primary_10_1055_a_1497_0693 crossref_primary_10_1016_j_idc_2017_05_003 crossref_primary_10_1056_NEJMoa2404991 crossref_primary_10_1016_j_cmi_2025_02_033 crossref_primary_10_1371_journal_pone_0272021 crossref_primary_10_1136_bmjopen_2020_038300 crossref_primary_10_1016_j_medmal_2017_01_007 crossref_primary_10_1007_s00101_017_0396_z crossref_primary_10_1093_jac_dkx528 crossref_primary_10_1136_bmjopen_2024_084981 crossref_primary_10_1186_s12887_017_0789_9 crossref_primary_10_1007_s11739_015_1223_7 crossref_primary_10_1097_ACO_0000000000000954 crossref_primary_10_1016_j_jmii_2024_05_010 crossref_primary_10_1186_s40560_022_00642_3 crossref_primary_10_12788_jhm_3414 crossref_primary_10_1016_j_medmal_2019_07_005 crossref_primary_10_1056_NEJMe2414037 crossref_primary_10_1371_journal_pone_0194858 crossref_primary_10_1016_j_jgar_2013_01_004 crossref_primary_10_1186_cc11421 crossref_primary_10_1128_JCM_01015_18 crossref_primary_10_1007_s10096_019_03467_5 crossref_primary_10_1016_j_jiac_2019_11_011 crossref_primary_10_1177_0885066618762747 crossref_primary_10_1016_j_iccn_2023_103549 crossref_primary_10_1007_s15010_017_1020_5 crossref_primary_10_1111_brv_12407 crossref_primary_10_1007_s00134_015_3853_7 crossref_primary_10_1016_j_ocl_2021_08_008 crossref_primary_10_1177_20499361211073248 crossref_primary_10_1136_bmjopen_2017_020439 crossref_primary_10_1093_femsre_fuv013 crossref_primary_10_1097_IPC_0000000000000362 crossref_primary_10_1016_j_jcrc_2023_154257 crossref_primary_10_1016_j_jinf_2021_10_017 crossref_primary_10_1016_j_ijantimicag_2017_12_007 crossref_primary_10_1093_jac_dkt424 crossref_primary_10_3389_fmed_2025_1617328 crossref_primary_10_1016_j_eclinm_2025_103397 crossref_primary_10_1007_s11908_021_00747_0 crossref_primary_10_1007_s00134_024_07634_x crossref_primary_10_1016_j_ijregi_2025_100639 crossref_primary_10_1097_MCC_0b013e328356cefe crossref_primary_10_1136_archdischild_2015_309132 crossref_primary_10_1093_cid_civ560 crossref_primary_10_1080_23120053_2015_1103956 crossref_primary_10_1093_cid_ciy1054 crossref_primary_10_1007_s15010_016_0885_z crossref_primary_10_1093_cid_ciy1057 crossref_primary_10_1186_s12879_022_07653_3 crossref_primary_10_1136_bmjopen_2017_017996 crossref_primary_10_1089_sur_2017_219 crossref_primary_10_1016_j_cmi_2015_05_018 crossref_primary_10_1089_sur_2017_218 crossref_primary_10_1186_1471_2334_14_235 crossref_primary_10_1016_j_cmi_2017_08_030 crossref_primary_10_3390_jcm12093188 crossref_primary_10_1080_17512433_2017_1369879 crossref_primary_10_1097_CCM_0000000000005337 crossref_primary_10_1016_j_cmi_2021_09_001 crossref_primary_10_1111_vec_12842 crossref_primary_10_1186_s13054_018_2206_7 crossref_primary_10_1186_s13054_020_02946_y crossref_primary_10_1007_s00101_017_0398_x crossref_primary_10_1128_spectrum_01067_25 crossref_primary_10_1089_sur_2020_241 crossref_primary_10_1007_s00134_015_3978_8 crossref_primary_10_1016_j_jiph_2021_08_021 crossref_primary_10_1016_j_pan_2016_03_019 crossref_primary_10_1186_s13063_018_2474_1 crossref_primary_10_1371_journal_pone_0163005 crossref_primary_10_1186_s13054_021_03660_z crossref_primary_10_1186_s13063_015_0688_z crossref_primary_10_1093_jac_dku338 crossref_primary_10_1186_1471_2334_14_489 crossref_primary_10_1093_cid_cix767 crossref_primary_10_1007_s00134_019_05878_6 crossref_primary_10_1093_jac_dks277 crossref_primary_10_1016_j_amjmed_2019_03_025 crossref_primary_10_3390_antibiotics12020302 crossref_primary_10_1007_s00134_021_06506_y crossref_primary_10_1186_s12887_022_03219_z crossref_primary_10_1186_s13063_019_4033_9 crossref_primary_10_12788_jhm_2927 crossref_primary_10_1007_s15010_021_01581_1 crossref_primary_10_1016_j_jcrc_2012_11_018 |
| Cites_doi | 10.1093/clinids/24.3.387 10.1097/QCO.0b013e3280555072 10.1016/j.ijantimicag.2011.07.016 10.1016/j.urology.2007.09.002 10.1093/cid/cir034 10.1378/chest.118.1.146 10.1164/ajrccm.163.7.9912080 10.1097/01.CCM.0000217961.75225.E9 10.2165/00003495-200868130-00004 10.1001/jama.2009.1754 10.1016/j.amjmed.2007.04.023 10.1016/j.annfar.2008.10.021 10.1164/rccm.200405-644ST 10.1093/cid/cir063 10.1086/500318 10.1086/649554 10.1097/00045391-199907000-00007 10.1001/jama.290.19.2588 10.1016/S0140-6736(02)09994-4 10.1086/526535 10.1093/jac/dkg447 10.1136/bmj.38049.490255.DE 10.1086/519283 10.1016/j.ijantimicag.2007.06.017 10.1016/S0022-5347(17)48870-7 10.1093/cid/ciq257 10.1093/jac/dkh356 10.1086/497143 10.1542/peds.2005-0917 10.1089/sur.2006.7.419 10.1136/bmj.332.7554.1355 10.7326/0003-4819-106-3-341 10.1111/j.1651-2227.1981.tb06245.x 10.1086/599376 10.1001/jama.283.12.1583 10.1093/clind/24.4.584 10.1038/sj.jp.7200416 10.1016/j.clinthera.2008.10.007 10.1093/tropej/fml054 10.1016/0924-8579(95)00011-V 10.1185/030079907X233340 10.7326/0003-4819-119-4-199308150-00010 10.1001/archinte.164.15.1669 10.1007/s11605-007-0277-x 10.1007/PL00008360 10.1086/511159 10.1016/0016-5085(91)90677-D 10.1093/jac/dkm119 10.1111/j.0954-6820.1988.tb15899.x 10.1086/421354 10.1086/377539 10.1136/bmj.327.7414.557 10.1016/S0399-077X(02)00384-0 10.1038/sj.jp.7210949 10.1001/archinte.1989.00390030039007 10.1001/archinte.163.8.972 |
| ContentType | Journal Article |
| Copyright | Havey et al.; licensee BioMed Central Ltd. 2011 COPYRIGHT 2011 BioMed Central Ltd. Copyright ©2011 Havey et al.; licensee BioMed Central Ltd. 2011 Havey et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Havey et al.; licensee BioMed Central Ltd. 2011 – notice: COPYRIGHT 2011 BioMed Central Ltd. – notice: Copyright ©2011 Havey et al.; licensee BioMed Central Ltd. 2011 Havey et al.; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1186/cc10545 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1364-8535 1466-609X |
| EndPage | R267 |
| ExternalDocumentID | PMC3388653 A274437855 22085732 10_1186_cc10545 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Canadian Institutes of Health Research |
| GroupedDBID | --- 0R~ 29F 2WC 4.4 53G 5GY 5VS 6J9 6PF AAFWJ AAJSJ AASML AAWTL ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C6C CS3 DIK E3Z EBLON EBS EJD EMOBN F5P GROUPED_DOAJ GX1 H13 HYE IAO IHR INH INR ITC KQ8 OK1 PQQKQ RBZ ROL RPM RSV SJN SMD SOJ SV3 TR2 U2A WOQ YOC .6V AAYXX CITATION 7X7 88E 8FI 8FJ ABUWG AFKRA ALIPV BENPR BPHCQ BVXVI C1A CCPQU CGR CUY CVF EBD ECM EIF FYUFA HMCUK M1P NPM O5R O5S PHGZM PHGZT PIMPY PJZUB PPXIY PROAC PSQYO UKHRP 7X8 5PM |
| ID | FETCH-LOGICAL-c534t-9d828da2380b7f6c5c40fbcde433980ded2650beb49e9047be1792f59447310e3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 148 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000306087200061&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1364-8535 1466-609X |
| IngestDate | Thu Aug 21 13:53:40 EDT 2025 Fri Sep 05 10:34:21 EDT 2025 Sat Nov 29 13:37:38 EST 2025 Sun Nov 23 09:02:26 EST 2025 Mon Jul 21 05:31:27 EDT 2025 Tue Nov 18 21:11:07 EST 2025 Sat Nov 29 06:32:30 EST 2025 Sat Sep 06 07:29:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Clinical Cure Soft Tissue Infection Pyelonephritis Bloodstream Infection Spontaneous Bacterial Peritonitis |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c534t-9d828da2380b7f6c5c40fbcde433980ded2650beb49e9047be1792f59447310e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | https://link.springer.com/10.1186/cc10545 |
| PMID | 22085732 |
| PQID | 959139253 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3388653 proquest_miscellaneous_959139253 gale_infotracmisc_A274437855 gale_infotracacademiconefile_A274437855 pubmed_primary_22085732 crossref_citationtrail_10_1186_cc10545 crossref_primary_10_1186_cc10545 springer_journals_10_1186_cc10545 |
| PublicationCentury | 2000 |
| PublicationDate | 20111115 |
| PublicationDateYYYYMMDD | 2011-11-15 |
| PublicationDate_xml | – month: 11 year: 2011 text: 20111115 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Critical care (London, England) |
| PublicationTitleAbbrev | Crit Care |
| PublicationTitleAlternate | Crit Care |
| PublicationYear | 2011 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | WF Ehni (9776_CR52) 1989; 149 P Leophonte (9776_CR39) 2002; 32 E Rubinstein (9776_CR12) 2007; 30 JS Solomkin (9776_CR15) 2010; 50 MT Hecker (9776_CR9) 2003; 163 EH Ibrahim (9776_CR7) 2000; 118 M Fekih Hassen (9776_CR41) 2009; 28 R Gleckman (9776_CR45) 1985; 133 JA Jernigan (9776_CR51) 1993; 119 J Chastre (9776_CR42) 2003; 290 JP Higgins (9776_CR25) 2003; 327 K Gupta (9776_CR17) 2011; 52 N Daneman (9776_CR20) 2011; 38 JZ Li (9776_CR23) 2007; 120 HA Klausner (9776_CR56) 2007; 23 WD Engle (9776_CR31) 2000; 20 RE Siegel (9776_CR38) 1999; 6 H Jernelius (9776_CR47) 1988; 223 E Vuori-Holopainen (9776_CR32) 2000; 159 R el Moussaoui (9776_CR40) 2006; 332 LB Rice (9776_CR10) 2008; 46 LA Mandell (9776_CR13) 2007; 44 American Thoracics Society/Infectious Diseases Society of America (9776_CR14) 2005; 171 TL Hedrick (9776_CR53) 2006; 7 G Chowdhary (9776_CR26) 2006; 52 LM Dunbar (9776_CR37) 2003; 37 G Agarwal (9776_CR33) 2004; 328 C Cheng (9776_CR48) 2006; 117 KG Kyriakidou (9776_CR21) 2008; 30 J Valles (9776_CR2) 1997; 24 JC McGregor (9776_CR8) 2007; 45 ZI Chaudhry (9776_CR29) 2000; 10 A Kumar (9776_CR6) 2006; 34 LA Mermel (9776_CR16) 2009; 49 R de Gier (9776_CR43) 1995; 6 A Basoli (9776_CR27) 2008; 12 TM File (9776_CR55) 2004; 39 A Corona (9776_CR19) 2003; 53 BA Runyon (9776_CR28) 1991; 100 J Peterson (9776_CR57) 2008; 71 DA Talan (9776_CR58) 2000; 283 M Garrouste-Orgeas (9776_CR5) 2006; 42 G Tellier (9776_CR36) 2004; 54 MP Weinstein (9776_CR3) 1997; 24 NM Scalera (9776_CR54) 2007; 20 WE Stamm (9776_CR44) 1987; 106 WD Engle (9776_CR30) 2003; 23 C Liu (9776_CR50) 2011; 52 9776_CR24 DL Stevens (9776_CR18) 2005; 41 TM File Jr (9776_CR35) 2007; 60 G Dimopoulos (9776_CR22) 2008; 68 B Renaud (9776_CR4) 2001; 163 J Pylkkanen (9776_CR46) 1981; 70 Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group (9776_CR34) 2002; 360 JL Vincent (9776_CR1) 2009; 302 Y Hayashi (9776_CR11) 2011; 52 MJ Hepburn (9776_CR49) 2004; 164 22236377 - Crit Care. 2012 Jan 09;16(1):403. doi: 10.1186/cc10590. |
| References_xml | – volume: 24 start-page: 387 year: 1997 ident: 9776_CR2 publication-title: Clin Infect Dis doi: 10.1093/clinids/24.3.387 – volume: 20 start-page: 177 year: 2007 ident: 9776_CR54 publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0b013e3280555072 – volume: 38 start-page: 480 year: 2011 ident: 9776_CR20 publication-title: Int J Antimicr Agents doi: 10.1016/j.ijantimicag.2011.07.016 – volume: 71 start-page: 17 year: 2008 ident: 9776_CR57 publication-title: Urology doi: 10.1016/j.urology.2007.09.002 – volume: 52 start-page: 1 year: 2011 ident: 9776_CR50 publication-title: Clin Infect Dis doi: 10.1093/cid/cir034 – volume: 118 start-page: 146 year: 2000 ident: 9776_CR7 publication-title: Chest doi: 10.1378/chest.118.1.146 – volume: 163 start-page: 1584 year: 2001 ident: 9776_CR4 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.163.7.9912080 – volume: 34 start-page: 1589 year: 2006 ident: 9776_CR6 publication-title: Crit Care Med doi: 10.1097/01.CCM.0000217961.75225.E9 – volume: 68 start-page: 1841 year: 2008 ident: 9776_CR22 publication-title: Drugs doi: 10.2165/00003495-200868130-00004 – volume: 302 start-page: 2323 year: 2009 ident: 9776_CR1 publication-title: JAMA doi: 10.1001/jama.2009.1754 – volume: 120 start-page: 783 year: 2007 ident: 9776_CR23 publication-title: Am J Med doi: 10.1016/j.amjmed.2007.04.023 – volume: 28 start-page: 16 year: 2009 ident: 9776_CR41 publication-title: Ann Fr Anesth Reanim doi: 10.1016/j.annfar.2008.10.021 – volume: 171 start-page: 388 year: 2005 ident: 9776_CR14 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200405-644ST – ident: 9776_CR24 – volume: 52 start-page: 1232 year: 2011 ident: 9776_CR11 publication-title: Clin Infect Dis doi: 10.1093/cid/cir063 – volume: 42 start-page: 1118 year: 2006 ident: 9776_CR5 publication-title: Clin Infect Dis doi: 10.1086/500318 – volume: 50 start-page: 133 year: 2010 ident: 9776_CR15 publication-title: Clin Infect Dis doi: 10.1086/649554 – volume: 6 start-page: 217 year: 1999 ident: 9776_CR38 publication-title: Am J Ther doi: 10.1097/00045391-199907000-00007 – volume: 290 start-page: 2588 year: 2003 ident: 9776_CR42 publication-title: JAMA doi: 10.1001/jama.290.19.2588 – volume: 360 start-page: 835 year: 2002 ident: 9776_CR34 publication-title: Lancet doi: 10.1016/S0140-6736(02)09994-4 – volume: 46 start-page: 491 year: 2008 ident: 9776_CR10 publication-title: Clin Infect Dis doi: 10.1086/526535 – volume: 53 start-page: 849 year: 2003 ident: 9776_CR19 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkg447 – volume: 328 start-page: 791 year: 2004 ident: 9776_CR33 publication-title: BMJ doi: 10.1136/bmj.38049.490255.DE – volume: 45 start-page: 329 year: 2007 ident: 9776_CR8 publication-title: Clin Infect Dis doi: 10.1086/519283 – volume: 30 start-page: 76 year: 2007 ident: 9776_CR12 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2007.06.017 – volume: 133 start-page: 176 year: 1985 ident: 9776_CR45 publication-title: J Urol doi: 10.1016/S0022-5347(17)48870-7 – volume: 52 start-page: e103 year: 2011 ident: 9776_CR17 publication-title: Clin Infect Dis doi: 10.1093/cid/ciq257 – volume: 54 start-page: 515 year: 2004 ident: 9776_CR36 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkh356 – volume: 41 start-page: 1373 year: 2005 ident: 9776_CR18 publication-title: Clin Infect Dis doi: 10.1086/497143 – volume: 117 start-page: e84 year: 2006 ident: 9776_CR48 publication-title: Pediatrics doi: 10.1542/peds.2005-0917 – volume: 7 start-page: 419 year: 2006 ident: 9776_CR53 publication-title: Surg Infect doi: 10.1089/sur.2006.7.419 – volume: 332 start-page: 1355 year: 2006 ident: 9776_CR40 publication-title: BMJ doi: 10.1136/bmj.332.7554.1355 – volume: 106 start-page: 341 year: 1987 ident: 9776_CR44 publication-title: Ann Intern Med doi: 10.7326/0003-4819-106-3-341 – volume: 70 start-page: 885 year: 1981 ident: 9776_CR46 publication-title: Acta Paediatr Scand doi: 10.1111/j.1651-2227.1981.tb06245.x – volume: 49 start-page: 1 year: 2009 ident: 9776_CR16 publication-title: Clin Infect Dis doi: 10.1086/599376 – volume: 283 start-page: 1583 year: 2000 ident: 9776_CR58 publication-title: JAMA doi: 10.1001/jama.283.12.1583 – volume: 24 start-page: 584 year: 1997 ident: 9776_CR3 publication-title: Clin Infect Dis doi: 10.1093/clind/24.4.584 – volume: 20 start-page: 421 year: 2000 ident: 9776_CR31 publication-title: J Perinatol doi: 10.1038/sj.jp.7200416 – volume: 30 start-page: 1859 year: 2008 ident: 9776_CR21 publication-title: Clin Ther doi: 10.1016/j.clinthera.2008.10.007 – volume: 52 start-page: 427 year: 2006 ident: 9776_CR26 publication-title: J Trop Pediatr doi: 10.1093/tropej/fml054 – volume: 6 start-page: 27 year: 1995 ident: 9776_CR43 publication-title: Int J Antimicrob Agents doi: 10.1016/0924-8579(95)00011-V – volume: 23 start-page: 2637 year: 2007 ident: 9776_CR56 publication-title: Curr Med Res Opin doi: 10.1185/030079907X233340 – volume: 119 start-page: 304 year: 1993 ident: 9776_CR51 publication-title: Ann Intern Med doi: 10.7326/0003-4819-119-4-199308150-00010 – volume: 164 start-page: 1669 year: 2004 ident: 9776_CR49 publication-title: Arch Intern Med doi: 10.1001/archinte.164.15.1669 – volume: 10 start-page: 284 year: 2000 ident: 9776_CR29 publication-title: JCPSP – volume: 12 start-page: 592 year: 2008 ident: 9776_CR27 publication-title: J Gastrointest Surg doi: 10.1007/s11605-007-0277-x – volume: 159 start-page: 878 year: 2000 ident: 9776_CR32 publication-title: Eur J Pediatr doi: 10.1007/PL00008360 – volume: 44 start-page: S27 year: 2007 ident: 9776_CR13 publication-title: Clin Infect Dis doi: 10.1086/511159 – volume: 100 start-page: 1737 year: 1991 ident: 9776_CR28 publication-title: Gastroenterology doi: 10.1016/0016-5085(91)90677-D – volume: 60 start-page: 112 year: 2007 ident: 9776_CR35 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkm119 – volume: 223 start-page: 469 year: 1988 ident: 9776_CR47 publication-title: Acta Med Scand doi: 10.1111/j.0954-6820.1988.tb15899.x – volume: 39 start-page: S159 year: 2004 ident: 9776_CR55 publication-title: Clin Infect Dis doi: 10.1086/421354 – volume: 37 start-page: 752 year: 2003 ident: 9776_CR37 publication-title: Clin Infect Dis doi: 10.1086/377539 – volume: 327 start-page: 557 year: 2003 ident: 9776_CR25 publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 32 start-page: 369 year: 2002 ident: 9776_CR39 publication-title: Medecine et Maladies Infectieuses doi: 10.1016/S0399-077X(02)00384-0 – volume: 23 start-page: 372 year: 2003 ident: 9776_CR30 publication-title: J Perinatol doi: 10.1038/sj.jp.7210949 – volume: 149 start-page: 533 year: 1989 ident: 9776_CR52 publication-title: Arch Intern Med doi: 10.1001/archinte.1989.00390030039007 – volume: 163 start-page: 972 year: 2003 ident: 9776_CR9 publication-title: Arch Intern Med doi: 10.1001/archinte.163.8.972 – reference: 22236377 - Crit Care. 2012 Jan 09;16(1):403. doi: 10.1186/cc10590. |
| SSID | ssj0017863 |
| Score | 2.428245 |
| SecondaryResourceType | review_article |
| Snippet | Introduction
The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as... The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as... Introduction The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | R267 |
| SubjectTerms | Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antibiotics Bacteremia Bacteremia - drug therapy Catheter-Related Infections - drug therapy Critical Care Medicine Drug therapy Emergency Medicine Humans Intensive Intraabdominal Infections - drug therapy Medicine Medicine & Public Health Patient outcomes Pneumonia, Bacterial - drug therapy Pyelonephritis - drug therapy Soft Tissue Infections - drug therapy Time Factors |
| Title | Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis |
| URI | https://link.springer.com/article/10.1186/cc10545 https://www.ncbi.nlm.nih.gov/pubmed/22085732 https://www.proquest.com/docview/959139253 https://pubmed.ncbi.nlm.nih.gov/PMC3388653 |
| Volume | 15 |
| WOSCitedRecordID | wos000306087200061&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1364-8535 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: RBZ dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1364-8535 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: DOA dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: Springer Nature - Connect here FIRST to enable access customDbUrl: eissn: 1364-8535 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: RSV dateStart: 19970401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFH6iBSEuZSnLQBkZCdFT1BDv3MpScaFCpaARl8hbRCSaQZ2ZSv33fXacoZleQIpy8Yvl-K1e3vcAXjNDhfSVLbTUoWBoJwvlbVk4p2xTcdcI3xebkMfHajbTXzNY9GK47T4cSSZLndRaiQPnMBRgfAtuo49TUQdPvv1YHxhIJWifE3udeORsNk3uNZ-zeR9y41A0-Zqj-_8xygewkwNKcthLwEO4FbpHcPdLPjLfhdOPq57JZN4QnMbWtnMkJX3i1SXBoJXYBNkczlrzjhjyF9yZ9Ikt-JknZ2FpCpMhTB7D96NPpx8-F7mUQuE4ZctCe1xZeYP-ubSyEY47VjbW-cAo1ar0wVcYqtlgmQ66ZNIGVNSq4ZoxiQFgoE9gu5t34RkQaTHqKBlFViqmmbD-rRDae4wEZWMMn8CbYc5rl3HGY7mL33VabyhR5zmaAFkT_umhNW6S7Eem1VHZsA9ncs4AjiTCVtWHEd-QSsWRcm9EiUriRs1kYHsdm-LNsi7MV4ta8wiMWnE6gae9FKwHU6X6pbSagBzJx5ogQnOPW7r2V4LoxoW_ErHPV4OU1Nk2LDb_8fk_0LyAe2kvOz58D7aX56vwEu64i2W7OJ_ClpypadpNwPfJ-5_TpBtXOnwL9A |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BQdALz0IXChgJwSlqiN_cKqAqol0hWFBvll9RI9Es6u4i8e8ZO8nSLBeQcvPEcjxPZ8bfALxglgoZKldoqWPB0E4WKriy8F65uuK-FqFrNiGnU3V6qj_1YNGLodp9SElmS53VWol97zEUYPwqXGPoplL13ucv39YJA6kE7e7EXiYeOZtNk3vJ52zWQ24kRbOvObz9H6u8A7f6gJIcdBJwF67E9h7cOOlT5vdh9m7VMZnMa4Lb2LhmjqSku3j1i2DQSlyGbI7njX1DLPkD7ky6iy34WiDncWkL20OY7MDXw_ezt0dF30qh8JyyZaEDnqyCRf9cOlkLzz0ra-dDZJRqVYYYKgzVXHRMR10y6SIqalVzzZjEADDSB7DVztu4C0Q6jDpKRpGVimkmXHgthA4BI0FZW8sn8HLYc-N7nPHU7uK7yecNJUy_RxMga8IfHbTG3ySvEtNMUjacw9v-zgCuJMFWmYOEb0il4ki5N6JEJfGjYTKw3aShVFnWxvlqYTRPwKgVpxN42EnBejFV7l9KqwnIkXysCRI093ikbc4yRDce_JVIcz4fpMT0tmGx-Y2P_oHmGdw8mp0cm-MP04-PYTv_104P34Ot5cUqPoHr_ueyWVw8zVrxG_RsC-w |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VgiouvB8LBYyE4BQ1xG9uFWUFAlaVKKg3y6-ISDRbdbNI_HvGcbI0ywUh5eYvlmPPeMYZzzcAL5ilQobKFVrqWDDcJwsVXFl4r1xdcV-LkItNyMVCnZ7q4x3gYy5Mf9t9DEnmnIbE0tR2B-ehziquxIH36BYwfgWuslQpKB3Sv3zbBA-kEjTnx14GTwzP9vZ7yf5s343cCpD2dmd-8z9HfAtuDI4mOcyScRt2YnsH9j4PofS7cHK0zotPljXB6W1cs0QoyQlZvwg6s8T1VM7xrLFviCV_SJ9JTnjB1wI5i50t7EBtcg--zt-dvH1fDCUWCs8p6wod8MQVLNrt0slaeO5ZWTsfIqNUqzLEUKEL56JjOuqSSRdRgauaa8YkOoaR3ofddtnGh0CkQ2-kZBSXWDHNhAuvhdAhoIcoa2v5DF6O82_8wD-eymD8MP05RAkzzNEMyAZ4nik3_oa8SgtokhJiH94OuQQ4kkRnZQ4T7yGViiNyf4JE5fGTZjKKgElN6cZZG5frldE8EaZWnM7gQZaIzWCqvq4prWYgJ7KyASTK7mlL23zvqbspVUqkPp-PEmOGPWO1_Y2P_gHzDPaOj-bm04fFx8dwvf_dnR6-D7vdxTo-gWv-Z9esLp72CvIbC10U0A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Duration+of+antibiotic+therapy+for+bacteremia%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Havey%2C+Thomas+C&rft.au=Fowler%2C+Robert+A&rft.au=Daneman%2C+Nick&rft.date=2011-11-15&rft.eissn=1466-609X&rft.volume=15&rft.issue=6&rft.spage=R267&rft_id=info:doi/10.1186%2Fcc10545&rft_id=info%3Apmid%2F22085732&rft.externalDocID=22085732 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon |